RADNOR, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory documents while maintaining a "human in the loop" approach to the use of gen ...

Core Insights - Certara, Inc. has launched its next-generation CoAuthor regulatory writing software, which integrates generative AI with traditional writing tools to enhance the efficiency of medical writing in drug development [1][3]. Company Overview - Certara is a leader in model-informed drug development, providing biosimulation software and services to accelerate drug discovery and development [5]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries [5]. Product Features - CoAuthor is designed specifically for medical writers, combining generative AI, document templates, and Microsoft Word integration to streamline the creation of regulatory documents [1][3]. - The platform allows for a "human in the loop" approach, ensuring that medical writers can maintain control over the content while benefiting from AI-generated suggestions [1][4]. - CoAuthor improves the time to first draft by at least 30%, significantly reducing drafting time while enhancing content quality and consistency [4]. Industry Context - Medical writing has remained largely unchanged for the past two decades, relying on manual processes that are increasingly inadequate for the complexities of modern drug development [2]. - The demand for secure, specialized generative AI solutions in life sciences is growing, as companies seek to enhance their regulatory and medical writing capabilities [3].

About Certara Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include nearly 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at www.certara.com. RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies ...

RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel. "Rona and Daniel are leaders in their fields. They have proven track records of growing teams and building high-performing businesses," said William F. Feehery Ph.D., CEO, Certara. "I'm confident they will further Certara's mission of accelerating medicines to patients through the del ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2024 was $96.7 million, representing a year-over-year growth of 7% on a reported basis and 6% on a constant currency basis [3][77] - Adjusted EBITDA for Q1 2024 was $29.1 million, with an adjusted EBITDA margin of 30% [59][121] - Net loss for Q1 2024 was $4.7 million compared to net income of $1.4 million in Q1 2023 [79] - Adjusted diluted earnings per share for Q1 2024 was $0.10 compared to $0.12 in the prior year [59] Business Line Data and Key Metrics Changes - Software revenue was $39.3 million in Q1 2024, reflecting a 19% increase year-over-year on a reported basis and 18% on a constant currency basis [55][77] - Services revenue was $57.3 million in Q1 2024, flat compared to the prior year [76][78] - Software bookings for Q1 2024 were $33.1 million, an increase of 8% from the prior year [57] - Technology-driven services bookings for Q1 2024 were $72.7 million, down 11% year-over-year [78] Market Data and Key Metrics Changes - The software net retention rate for Q1 2024 was 114%, consistent with the long-term growth profile [12] - Trailing 12-month software bookings were $139.5 million, up 11% year-over-year [12] - The services business is recovering following cautious customer spending in 2023, with stable customer activity reported [76] Company Strategy and Development Direction - The company launched Certara Cloud, a platform integrating access to its software suite, which is currently used by 15 of the top 30 biopharmaceutical companies [4] - The focus remains on expanding the commercial footprint and enhancing biosimulation capabilities while improving product usability [5][75] - Investments are being made in sales and marketing, as well as R&D, to drive growth and enhance software offerings [28][58] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery of end markets throughout 2024, although funding has not yet translated into bookings and sales [9][46] - The company anticipates a stronger second half of 2024, with expectations for revenue growth of 9% to 13% compared to 2023 [14][38] - Management noted that the guidance does not include any benefits from the biotech funding environment, which could potentially enhance performance [48][104] Other Important Information - The company ended Q1 2024 with $224.8 million in cash and cash equivalents and $287.8 million in outstanding borrowings [14] - G&A expenses increased to $23 million from $19.8 million in Q1 2023, primarily due to changes related to the acquisition of Vyasa [13] Q&A Session Summary Question: Insights on services bookings and trends - Management noted that software bookings were impacted by timing, with some large deals moving to April, but they remain confident in the outlook [21][23] Question: Contribution from inorganic bookings - Inorganic bookings were around 2% of total bookings, with expectations for acceleration as the year progresses [24][25] Question: Margin progression and cost increases - Management indicated that increased costs were investments in sales and R&D, and they expect margin improvement as revenue grows in the second half of the year [28][44] Question: Visibility on services revenue growth - Management stated that while stability is observed, an inflection point in services bookings has not yet been reached, with expectations for improvement in the second half of the year [90][110] Question: Impact of biotech funding on bookings - Management clarified that while they are optimistic about the funding environment, it has not yet translated into bookings, with expectations for potential benefits in the latter half of the year [46][110]

Certara, Inc. (CERT) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.09, delivering a surprise of -18.18%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Certara, which belongs to t ...

The net amount of deferred gains related to derivative instruments designated as cash flow hedges that is expected to be reclassified from accumulated other comprehensive gains into earnings over the next twelve months is $5,041. The Company's revenue consists of fees for perpetual and term licenses for its software products, post-contract customer support (referred to as maintenance), software as a service ("SaaS"), and professional services including training and other revenue. Revenue is recognized upon ...

Certara Reports First Quarter 2024 Financial Results Reiterates Full Year 2024 Financial Guidance First Quarter Highlights: • Services revenue was $57.3 million, flat compared to $57.3 million in the first quarter of 2023. • Adjusted EBITDA was $29.1 million, compared to $32.3 million in the first quarter of 2023. "We began 2024 with strong financial performance in software, driven by an impressive Net Retention Ratio of 114%, while our services business performed in line with our expectations. As we work t ...

PRINCETON, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions. Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to modeling and analysis of clinical trial results. "This reusable suite of shared platform services enables us to both integrate ...

PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced ...